Cargando…

Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial

BACKGROUND: Few studies have so far been done about the role of follicle stimulating hormone (FSH) in final oocyte maturation. However, none of these studies have been performed solely on normoresponder patients. This study aimed to determine whether oocyte maturation, as well as fertilization and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansaripour, Soheila, Tamizi, Nayereh, Sadeghi, Mohammad Reza, Mohammad-Akbari, Azam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royan Institute 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396009/
https://www.ncbi.nlm.nih.gov/pubmed/36029051
http://dx.doi.org/10.22074/IJFS.2021.532258.1141
_version_ 1784771832566513664
author Ansaripour, Soheila
Tamizi, Nayereh
Sadeghi, Mohammad Reza
Mohammad-Akbari, Azam
author_facet Ansaripour, Soheila
Tamizi, Nayereh
Sadeghi, Mohammad Reza
Mohammad-Akbari, Azam
author_sort Ansaripour, Soheila
collection PubMed
description BACKGROUND: Few studies have so far been done about the role of follicle stimulating hormone (FSH) in final oocyte maturation. However, none of these studies have been performed solely on normoresponder patients. This study aimed to determine whether oocyte maturation, as well as fertilization and pregnancy rates, could be improved in normoresponder women with concomitant FSH and human chorionic gonadotropin (hCG) trigger compared to those with the hCG trigger alone. MATERIALS AND METHODS: In this prospective randomized clinical trial, 117 normoresponder women, aged 19-40 years who were candidates for the gonadotropin-releasing hormone (GnRH) antagonist protocol at Avicenna Infertility treatment Center, were enrolled and claasified in two groups. Final oocyte maturation was triggered using 10000 IU of hCG plus 450 IU of FSH in the first group (59 subjects) and 10000 IU of hCG alone in the second group (58 subjects). The primary outcome was clinical pregnancy rate. RESULTS: Mean age of the patients was 33.21 ± 4.41 years. There was no difference in clinical pregnancy among the two groups (30.9% vs. 25.5%, P=0.525). There was no statistically significant difference in fertilization rate (80.0% vs. 74.1%, P=0.106), implantation rates (18.9% vs. 16.7%, P=0.352), and chemical pregnancy rates (38.2% vs. 32.7%, P=0.550). Oocyte maturation rate (84.2% vs. 73.6%, P<0.001), 2 pronuclei (2PNs) (6.53 ± 2.54 vs. 5.36 ± 2.85, P=0.021) and total embryos (5.85 ± 2.43 vs. 4.91 ± 2.58, P=0.046) were significantly higher in the first group. CONCLUSION: Adding FSH to hCG for oocyte triggering, significantly improved oocyte maturation rates and total embryos. While there was no significant difference in the clinical and chemical pregnancy rates, between these two groups (registration number: IRCT20190108042285N1).
format Online
Article
Text
id pubmed-9396009
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Royan Institute
record_format MEDLINE/PubMed
spelling pubmed-93960092022-08-28 Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial Ansaripour, Soheila Tamizi, Nayereh Sadeghi, Mohammad Reza Mohammad-Akbari, Azam Int J Fertil Steril Original Article BACKGROUND: Few studies have so far been done about the role of follicle stimulating hormone (FSH) in final oocyte maturation. However, none of these studies have been performed solely on normoresponder patients. This study aimed to determine whether oocyte maturation, as well as fertilization and pregnancy rates, could be improved in normoresponder women with concomitant FSH and human chorionic gonadotropin (hCG) trigger compared to those with the hCG trigger alone. MATERIALS AND METHODS: In this prospective randomized clinical trial, 117 normoresponder women, aged 19-40 years who were candidates for the gonadotropin-releasing hormone (GnRH) antagonist protocol at Avicenna Infertility treatment Center, were enrolled and claasified in two groups. Final oocyte maturation was triggered using 10000 IU of hCG plus 450 IU of FSH in the first group (59 subjects) and 10000 IU of hCG alone in the second group (58 subjects). The primary outcome was clinical pregnancy rate. RESULTS: Mean age of the patients was 33.21 ± 4.41 years. There was no difference in clinical pregnancy among the two groups (30.9% vs. 25.5%, P=0.525). There was no statistically significant difference in fertilization rate (80.0% vs. 74.1%, P=0.106), implantation rates (18.9% vs. 16.7%, P=0.352), and chemical pregnancy rates (38.2% vs. 32.7%, P=0.550). Oocyte maturation rate (84.2% vs. 73.6%, P<0.001), 2 pronuclei (2PNs) (6.53 ± 2.54 vs. 5.36 ± 2.85, P=0.021) and total embryos (5.85 ± 2.43 vs. 4.91 ± 2.58, P=0.046) were significantly higher in the first group. CONCLUSION: Adding FSH to hCG for oocyte triggering, significantly improved oocyte maturation rates and total embryos. While there was no significant difference in the clinical and chemical pregnancy rates, between these two groups (registration number: IRCT20190108042285N1). Royan Institute 2022 2022-08-21 /pmc/articles/PMC9396009/ /pubmed/36029051 http://dx.doi.org/10.22074/IJFS.2021.532258.1141 Text en Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited. https://creativecommons.org/licenses/by-nc/3.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ansaripour, Soheila
Tamizi, Nayereh
Sadeghi, Mohammad Reza
Mohammad-Akbari, Azam
Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial
title Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial
title_full Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial
title_fullStr Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial
title_full_unstemmed Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial
title_short Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial
title_sort comparison of triggering final oocyte maturation with follicle stimulating hormone plus human chorionic gonadotropin, versus human chorionic gonadotropin alonein normoresponder women undergoing intracytoplasmic sperm injection: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396009/
https://www.ncbi.nlm.nih.gov/pubmed/36029051
http://dx.doi.org/10.22074/IJFS.2021.532258.1141
work_keys_str_mv AT ansaripoursoheila comparisonoftriggeringfinaloocytematurationwithfolliclestimulatinghormoneplushumanchorionicgonadotropinversushumanchorionicgonadotropinaloneinnormoresponderwomenundergoingintracytoplasmicsperminjectionarandomizedclinicaltrial
AT tamizinayereh comparisonoftriggeringfinaloocytematurationwithfolliclestimulatinghormoneplushumanchorionicgonadotropinversushumanchorionicgonadotropinaloneinnormoresponderwomenundergoingintracytoplasmicsperminjectionarandomizedclinicaltrial
AT sadeghimohammadreza comparisonoftriggeringfinaloocytematurationwithfolliclestimulatinghormoneplushumanchorionicgonadotropinversushumanchorionicgonadotropinaloneinnormoresponderwomenundergoingintracytoplasmicsperminjectionarandomizedclinicaltrial
AT mohammadakbariazam comparisonoftriggeringfinaloocytematurationwithfolliclestimulatinghormoneplushumanchorionicgonadotropinversushumanchorionicgonadotropinaloneinnormoresponderwomenundergoingintracytoplasmicsperminjectionarandomizedclinicaltrial